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Introduction
Heparin-binding epidermal-growth-factor (EGF)-like growth factor
(HB-EGF) is a ligand in the EGF receptor (EGFR) family that
activates the EGFR (Higashiyama et al., 1991) and ErbB4 (also
known as HER4) (Elenius et al., 1997), and binds heparan-sulfate
proteoglycans (HSPGs) present on the cell surface and in the
extracellular matrix (Higashiyama et al., 1991) by means of a
heparin-binding domain (HBD) (Thompson et al., 1994). As with
all EGFR-family ligands, HB-EGF is synthesized in pro-form as a
transmembrane protein that is proteolytically cleaved from the cell
surface to yield a soluble form that can activate receptors in
autocrine and/or paracrine mode (Harris et al., 2003; Singh and
Harris, 2005; Higashiyama et al., 2008) or bind to HSPGs.
However, HB-EGF also has the ability to signal in juxtacrine mode
by activating receptors on a neighboring cell while still being
anchored to the plasma membrane. HB-EGF associates with the
tetraspanin protein CD9, which enhances its juxtacrine activity
(Higashiyama et al., 1995; Iwamoto et al., 1991) and links HB-
EGF to 31 integrins (Nakamura et al., 1995). CD9 also interacts
with HB-EGF via its HBD (Sakuma et al., 1997).
HB-EGF juxtacrine signaling and autocrine and/or paracrine
signaling have been shown to elicit different phenotypes, with
autocrine and/or paracrine activity leading to cell proliferation and
migration (Higashiyama et al., 1991; Yahata et al., 2006), and
juxtacrine activity causing growth inhibition and in some cases
apoptosis (Iwamoto et al., 1999; Pan et al., 2002). HB-EGF
proteolytic cleavage and subsequent autocrine signaling drives
physiologically beneficial migration of a variety of tissue cells,
such as keratinocytes (Shirakata et al., 2005; Tokumaru et al.,
2000), corneal epithelial cells (Block et al., 2004; Xu et al., 2004),
smooth-muscle cells (Bakken et al., 2009), peritoneal mesothelial
cells (Faull et al., 2001) and mesenchymal stem cells (Ozaki et al.,
2007) during wound healing. Soluble HB-EGF stimulation is also
crucially involved in invasive motility of aggressive solid tumors,
particularly ovarian cancer (Yagi et al., 2008; Matsuzaki et al.,
2005; Tanaka et al., 2005; Miyamoto et al., 2004) among others
(Normanno et al., 2001).
We have previously shown that soluble HB-EGF can operate in
a highly localized spatial domain following its proteolytic release
(Yoshioka et al., 2005), owing to a combination of restricted
diffusion and fast binding to cell surface receptors. Both of these
localization processes might arise from interactions with HSPGs –
residing in extracellular matrix for the former, or on the cellular
glycocalyx for the latter. Moreover, human mammary epithelial
cells, driven by proteolytic release of the soluble autocrine EGF
ligand, migrate in a more directionally persistent manner compared
with cells treated with EGF ligand exogenously (Maheshwari et
al., 2001). We have shown by computational modeling that the
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Summary
Heparin-binding EGF-like growth factor (HB-EGF) is a ligand for EGF receptor (EGFR) and possesses the ability to signal in
juxtacrine, autocrine and/or paracrine mode, with these alternatives being governed by the degree of proteolytic release of the ligand.
Although the spatial range of diffusion of released HB-EGF is restricted by binding heparan-sulfate proteoglycans (HSPGs) in the
extracellular matrix and/or cellular glycocalyx, ascertaining mechanisms governing non-released HB-EGF localization is also important
for understanding its effects. We have employed a new method for independently tracking the localization of the extracellular EGF-
like domain of HB-EGF and the cytoplasmic C-terminus. A striking observation was the absence of the HB-EGF transmembrane pro-
form from the leading edge of COS-7 cells in a wound-closure assay; instead, this protein localized in regions of cell-cell contact. A
battery of detailed experiments found that this localization derives from a trans interaction between extracellular HSPGs and the HB-
EGF heparin-binding domain, and that disruption of this interaction leads to increased release of soluble ligand and a switch in cell
phenotype from juxtacrine-induced growth inhibition to autocrine-induced proliferation. Our results indicate that extracellular HSPGs
serve to sequester the transmembrane pro-form of HB-EGF at the point of cell-cell contact, and that this plays a role in governing the
balance between juxtacrine versus autocrine and paracrine signaling.
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EGFR system might be capable of producing spatially localized
autocrine signaling loops (Maly et al., 2004), and have found in
ensuing experimental studies that autocrine EGF drives migration
effectively (Joslin et al., 2007).
Because of the disparity in cell phenotypic responses to
juxtacrine HB-EGF signaling versus autocrine and/or paracrine
HB-EGF signaling, and the prospective importance of spatial
localization of both the transmembrane pro-form as well as the
soluble mature form, ascertaining mechanisms responsible for
governing localization and proteolytic cleavage of this ligand is
important for understanding its physiological and pathological
effects. Previous work has provided crucial insights into the roles
played by the membrane-anchoring domain of the ligand (Dong et
al., 2005), regulatory signaling pathways (Herrlich et al., 2008)
and extracellular-matrix HSPGs (Forsten-Williams et al., 2008).
Thus, we endeavor here to offer a contribution elucidating how
HSPGs in the cellular glycocalyx might influence localization
and/or release of HB-EGF.
Our goal is complicated by the growing evidence that the C-
terminal fragment of HB-EGF, consisting of the transmembrane
and cytoplasmic domains, might provide signaling information
separately from the extracellular domain (Higashiyama et al.,
2008). This fragment can translocate to the nucleus and reverse
gene repression of the transcriptional repressors promyelocytic
leukemia zinc finger protein (PLZF) and Bcl6 (Kinugasa et al.,
2007; Nanba et al., 2003). Therefore, in exploring processes
governing HB-EGF localization, it is imperative to distinguish the
extracellular EGF-like domain from the intracellular C-terminal
fragment, because they are both signaling molecules that can have
different localization after ligand cleavage. To address this
challenge, we incorporated different visualization tags at the
extracellular and intracellular domains of pro-HB-EGF. For the
former, we employed an acceptor peptide enabling biotinylation
for subsequent visualization with a streptavidin-conjugated
fluorophore and attached green fluorescent protein (GFP) to the C-
terminus for the latter. This construct facilitated novel examination
of interactions between HSPGs and membrane-anchored HB-EGF
(pro-HB-EGF), and consequent of the effects on ligand behavior.
A key finding is that pro-HB-EGF binding to HSPGs on adjacent
cells (in trans) is responsible for localization of pro-HB-EGF to
sites of cell-cell contact, prevents proteolytic cleavage and promotes
growth inhibition. This suggests a novel negative control
mechanism for HB-EGF autocrine and/or paracrine signaling
through sequestration of the pro-form by HSPGs.
Results
Pro-HB-EGF is localized at sites of cell-cell contact and is
absent from the wound edge
In order to independently track the C-terminal tail and the
extracellular domain of HB-EGF, a construct [acceptor-peptide
(AP)–HB-EGF–GFP] was designed to allow two-color tracking of
the localization of each fragment. A 14-amino-acid acceptor-peptide
tag was inserted before the shortest of the five N-terminal cleavage
sites in the extracellular domain of murine HB-EGF (Fig. 1A). The
acceptor-peptide tag allows for biotinylation of one specific lysine
residue in the sequence with the enzyme biotin ligase (BirA)
(Beckett et al., 1999) and subsequent fluorescent labeling with a
streptavidin-conjugated fluorophore (Fig. 1B). GFP was conjugated
to the cytoplasmic C-terminus of HB-EGF. Acceptor-peptide
labeling has the advantage that only the cell-surface pool of the
protein is labeled, because streptavidin is not permeable to the cell
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membrane, whereas the GFP signal represents the total intracellular
and plasma-membrane fraction of AP–HB-EGF–GFP. Insertion of
the acceptor peptide near the N-terminus of HB-EGF and
biotinylation of the tag did not affect the autocrine- and/or
paracrine-growth-factor activity of the protein, as assessed by
phosphorylation of the EGFR (Fig. 1C). Biotinylated AP–HB-EGF
was purified from the conditioned media of COS-7 cells with
heparin beads and used to stimulate naïve COS-7 cells. The purified
growth factor phosphorylated the EGFR at tyrosine 1148 in the
same manner as recombinant human HB-EGF (rhHB-EGF).
Additionally, a heparin-bead eluant from cells lacking AP–HB-
EGF expression to control for other heparin-binding growth factors
in the media showed little activation of the EGFR. The activity of
streptavidin-bound AP–HB-EGF was not assessed, because
streptavidin labeling was only performed immediately before image
acquisition. The localization of AP–HB-EGF (no GFP) and HB-
EGF–GFP (no AP) were identical, suggesting that neither insertion
of the AP nor GFP conjugation disrupted the localization of the
protein (see supplementary material Fig. S1).
AP–HB-EGF–GFP was successfully expressed in COS-7 cells
and labeled with a streptavidin-conjugated fluorophore. Cells were
co-transfected with the AP–HB-EGF–GFP construct and a plasmid
encoding BirA with an endoplasmic-reticulum localization sequence
(BirA-ER). BirA-ER expression leads to biotinylation of acceptor-
peptide-tagged proteins in the endoplasmic reticulum, utilizing
endogenous ATP and biotin supplemented in the media. After 24
hours of transfection, biotinylated proteins on the cell surface were
visualized with an engineered monovalent streptavidin-fluorophore
conjugate that does not promote protein crosslinking (Howarth et
al., 2006; Howarth and Ting, 2008) (mSA-AF568) in all
experiments with the exception of those in Fig. 2, in which
streptavidin-Cy5 was utilized after paraformaldehyde fixation to
Fig. 1. Acceptor-peptide labeling of HB-EGF. (A)Schematic representation
of mouse HB-EGF and the AP–HB-EGF–GFP construct. The arrows show
sites of modification, where EGFP was inserted at the C-terminus, and a 15-
amino-acid acceptor-peptide sequence (AP) was inserted before the HBD,
allowing biotinylation of all size isoforms of HB-EGF. Triangles represent
sites of cleavage at the N- and C-terminus of the human protein. The protein is
broken up into the secretory region (SEC), the pro-region (PRO), the heparin-
binding domain (HBD), the EGF-like domain (EGF),and the transmembrane
domain (TM). (B)The 15-amino-acid acceptor peptide (AP) sequence is
specifically biotinylated at one lysine residue by the enzyme BirA. After
biotinylation, the monovalent streptavidin tetramer with Alexa-Flour-568
attached, whose biotin-binding ability is dead in three of the four streptavidin
subunits, is used to visualize the acceptor peptide. (C)Biotinylated AP–HB-
EGF, purified from conditioned media with heparin beads, phosphorylated the
EGFR at tyrosine 1148 in the same manner as recombinant human HB-EGF
(rhHB-EGF) after 1 minute of stimulation. Treatment with an equal volume of
the control heparin-bead eluant, to control for other heparin-binding growth
factors in the media, shows little EGFR phosphorylation.
allow for co-staining with N-cadherin to visualize sites of cell-cell
contact. In some of the cells, only the GFP fluorescence (green,
Fig. 2) but no acceptor peptide labeling (red, Fig. 2) was observed,
which is probably due to inefficient co-transfection with BirA-ER.
In most cells, however, the colocalization of the HB-EGF
extracellular acceptor peptide (red, Fig. 2A), intracellular HB-EGF
C-terminal GFP tail (green, Fig. 2A), and the cell-cell adhesion
protein N-cadherin (white, Fig. 2A), showed that AP–HB-EGF–
GFP was present on the cell surface in the uncleaved pro-form at
sites of cell-cell contact, which is consistent with previous reports
(Goishi et al., 1995; Singh et al., 2004). The localization of the two
HB-EGF tags occasionally differed in the perinuclear region, where
only the GFP signal was present in intracellular vesicles, which are
probably part of the secretory pathway.
To determine the localization of the extracellular and intracellular
domains of HB-EGF during cell migration, a wound-closure assay
was employed to directionally control cell migration. Confluent
monolayers of COS-7 cells expressing AP–HB-EGF–GFP were
scratch-wounded and allowed to close for 4 hours, then the
extracellular biotinylated acceptor peptide was labeled with
streptavidin-Cy5 and sites of cell-cell contact were visualized with
N-cadherin immunostaining. We observed that both the extracellular
EGF-like domain (red, Fig. 2B) and cytoplasmic tail (green, Fig.
2B) of HB-EGF were completely absent from the wound edge, and
remained only at sites of cell-cell contact. Because of the well-
established role of HB-EGF in wound healing and chemotaxis, we
hypothesized that HB-EGF was preferentially cleaved from the
wound edge, inducing a polarized autocrine loop of EGFR
activation and cleavage at the leading edge of the cell. To test this
hypothesis, treatments aimed at blocking the autocrine signaling
loop were used on COS-7 cells before induction of the wound.
These included inhibition of proteolytic cleavage of pro-HB-EGF
with batimastat and GM6001, blocking of EGFR-ligand binding
with mAb225, inhibition of EGFR kinase activity with AG1478,
and inhibition of intracellular pathways downstream of the EGFR
using inhibitors to ERK (PD98059), Src (PP2) and PI3K
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(LY294002). However, none of these treatments prevented the loss
of HB-EGF from the leading edge of transfected cells after
wounding (see supplementary material Fig. S2). Pro-HB-EGF was
also localized only at sites of cell-cell contact and was absent from
any free edges in sparsely plated COS-7 cells (Fig. 2C). This
suggested that, rather than loss by cleavage, it was loss of cell-cell
contact that led to the absence of HB-EGF from the leading edge
of cells at the wound edge. The fraction of HB-EGF at sites of cell-
cell contact was quantified by measuring the amount of extracellular
AP–HB-EGF–GFP colocalized with N-cadherin immunostaining
normalized to the total HB-EGF area in cells that were sparse, at
the wound edge or in confluent monolayers. Additionally, the
fraction of the cell perimeter in cell-cell contact was calculated by
measuring the length of the cell periphery positive for N-cadherin
immunostaining, and normalizing this to the total cell periphery.
These data indicate that the fraction of HB-EGF at sites of cell-cell
contact remains constant at approximately 80%, independent of
the degree of cell-cell contact (Fig. 2D).
Role of the HBD in pro-HB-EGF localization to sites of cell-
cell contact
Because pro-HB-EGF was observed primarily at sites of cell-cell
contact, the question arose of what molecular interactions between
cells led to pro-HB-EGF concentration in this area. Because the
extracellular domain of pro-HB-EGF has the ability to interact
with cell-surface HSPGs, we hypothesized that this interaction
might control localization of HB-EGF to sites of cell-cell contact.
To test this hypothesis, we sought to compete for HSPG binding
to pro-HB-EGF with exogenous heparin and heparan sulfate. We
found that heparin and heparan sulfate (100 g/ml) dramatically
changed the localization of AP–HB-EGF–GFP (Fig. 3A,B). The
extracellular (red, Fig. 3) and intracellular (green, Fig. 3) domain
of AP–HB-EGF–GFP changed from localization primarily at sites
of cell-cell contact to a homogenous distribution over the entire
cell surface. Although the results shown in Fig. 3 are after 4 hours
of treatment, changes in pro-HB-EGF localization were observed
Fig. 2. Pro-HB-EGF is localized to sites of cell-cell contact. After 24 hours of transfection of COS-7 cells with AP–HB-EGF–GFP, the biotinylated extracellular
acceptor peptide in AP–HB-EGF–GFP was labeled with streptavidin-Cy5 (red) and imaged alongside the cytoplasmic tail conjugated to EGFP (green), N-cadherin
immunostaining (white) and phase contrast (A) in a confluent monolayer, (B) after 4 hours of wound healing and (C) in sparsely plated cells. Both the extracellular
and intracellular domains of HB-EGF were localized to sites of cell-cell contact (arrowheads) and absent from free edges. In B, cells are migrating from left to right
to close the wound. Each row represents the same field. Scale bars: 40m. (D)The fraction of HB-EGF colocalized with N-cadherin is relatively constant between
cells that were sparsely plated (triangles), at the wound edge (circles) or in a confluent monolayer (squares), despite different values for the fraction of the cell
perimeter in cell-cell contact. Data shown are average and standard deviation for n≥8.
as soon as 5 minutes following heparin addition (see supplementary
material Fig. S3). The minimum concentration required to change
the localization of HB-EGF after 4 hours was determined to be
approximately 0.1 g/ml of heparin and 10 g/ml of heparan
sulfate. The addition of the glycosaminoglycan chondroitin sulfate
(100 g/ml) did not affect the localization of AP–HB-EGF–GFP
(Fig. 3C). At 24 hours after the removal of heparin, AP–HB-EGF–
GFP localized back to sites of cell-cell contact as observed before
the addition of heparin (R.N.P., unpublished). These data indicate
that an interaction with HSPGs was responsible for localizing HB-
EGF to sites of cell-cell contact.
To further test our hypothesis, we aimed to diminish HSPG–
pro-HB-EGF interactions by manipulating HSPGs. Culture of
COS-7 cells expressing AP–HB-EGF–GFP for 24 hours with 50
mM sodium chlorate, an inhibitor of protein sulfation that blocks
the enzyme ATP sulfurylase (Baeuerle and Huttner, 1986), led to a
homogeneous distribution of AP–HB-EGF–GFP over the cell
surface (Fig. 4A), similar to the effect seen with the addition of
heparin. Additionally, digestion of cell-surface heparan sulfate with
heparinase III (1.6 mU/ml) for 4 hours similarly changed the
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localization of AP–HB-EGF–GFP, although some AP–HB-EGF–
GFP remained at sites of cell-cell contact (Fig. 4B). It might be
that some heparan-sulfate chains bound to HB-EGF are protected
from degradation by heparinase, as is the case with bFGF and
mammalian heparanase (Tumova and Bame, 1997). Competition
for 4 hours with an HBD peptide (100 M) consisting of the 21-
amino-acid sequence of the HBD of murine HB-EGF also changed
the localization of HB-EGF (Fig. 4C). Neither treatment with
heparin nor heparinase III affected cell-cell junctions, as assessed
by N-cadherin immunostaining after 4 hours of treatment (Fig.
4D). Thus, the reduction of all sulfated proteins with sodium
Fig. 3. Heparin and heparan sulfate changed the localization of pro-HB-
EGF from sites of cell-cell contact to a homogenous distribution over the
cell surface. After 24 hours of transfection of COS-7 cells with AP–HB-EGF–
GFP, the biotinylated, extracellular acceptor peptide in AP–HB-EGF–GFP was
labeled with monovalent streptavidin–Alexa-Fluor-568 (red, left) and imaged
alongside the cytoplasmic tail conjugated to EGFP (green, middle), and phase
contrast (right). Addition of (A) heparin (100g/ml) or (B) heparan sulfate
(100g/ml) for 4 hours changed the localization of both the extracellular and
intracellular domains of AP–HB-EGF–GFP to a diffuse distribution over the
cell surface, rather than at sites of cell-cell contact. (C)Addition of chondroitin
sulfate (100g/ml) for 4 hours had no effect on localization of AP–HB-EGF–
GFP. Each row represents the same field. Arrowheads indicate sites of cell-cell
contact. Scale bars: 40m.
Fig. 4. HSPGs target pro-HB-EGF to sites of cell-cell contact. After 24
hours of transfection of COS-7 cells with AP–HB-EGF–GFP cells were (A)
cultured for 24 hours with 50 mM sodium chlorate in media without penicillin-
streptomycin, (B) treated with heparinase III (1.6 mU/ml) for 4 hours, or (C)
incubated with a HBD peptide (100M) for 4 hours. The biotinylated,
extracellular acceptor peptide in AP–HB-EGF–GFP was labeled with
monovalent streptavidin–Alexa-Fluor-568 (red, left) and imaged alongside the
cytoplasmic tail conjugated to EGFP (green, middle), and phase-contrast
images were acquired (right), showing a reduction in the amount of pro-HB-
EGF at sites of cell-cell contact and a more homogenous distribution over the
cell surface. (A-C)Each row represents the same field. Arrowheads indicate
sites of cell-cell contact. (D)Confluent monolayers of COS-7 cells were
treated with heparin (100g/ml) or heparinase III (10 mU/ml) for 4 hours,
then immunostained for endogenous N-cadherin. There was no change in the
appearance of cell-cell junctions compared with an untreated controls. Scale
bars: 40m.
Table 1. Mutations in the HBD of HB-EGF
Name                                                                                               HBD sequence                                                             Number of basic residues
AP–HB-EGF–GFP                                                           KKKKKGKGLGKKRDPCLRKYK                                                                   12
AP–delHBD-HB-EGF–GFP                                             -------------DPCLRKYK                                                                    3
AP–97A-HB-EGF–GFP                                                   AAAAAGKGLGKKRDPCLRKYK                                                                    7
AP–105A-HB-EGF–GFP                                                 AAAAAGAGLGAAADPCLRKYK                                                                    3
AP–113A-HB-EGF–GFP                                                 AAAAAGAGLGAAADPCLAAYA                                                                    0
Mutations of basic lysine and arginine residues to alanine in the 21-amino-acid HBD of murine HB-EGF, with the unaltered HBD listed in the AP–HB-EGF–
GFP row. The number of basic amino acids left after mutation is shown for each mutant. -, represents amino acid deletion, rather than replacement.
chlorate, the removal of cell-surface heparan sulfate with heparinase
III and competition with an HBD peptide reduced the amount of
AP–HB-EGF–GFP at sites of cell-cell contact, leading to a more
homogenous distribution over the cell surface.
As a complementary approach to reduce the interaction of pro-
HB-EGF with cell-surface HSPGs, we made four different mutants
of AP–HB-EGF–GFP to inhibit the ability of HB-EGF to interact
with heparan sulfate (Table 1). The HBD of HB-EGF consists of
amino acids 93-113 of the mouse protein, which contains 12 basic
lysine and arginine residues that are responsible for the HB-EGF
interaction with heparin (Thompson et al., 1994). Residues 108-
113 lie within the EGF-like domain and contain three of the basic
amino acids. Deletion of the portion of the HBD that lies outside
the EGF-like domain (93-105) (AP–delHBD-HB-EGF–GFP) led
to a homogeneous distribution of HB-EGF over the cell surface
(Fig. 5A), similar to that seen with the addition of heparin. By
contrast, mutation of the first five positive lysine residues (93-97)
in the HBD to non-polar alanine (AP–97A-HB-EGF–GFP) had no
effect on the localization of HB-EGF (Fig. 5B). Mutation of an
additional four lysine and arginine residues to alanine (93-105)
(AP–105A-HB-EGF–GFP) was nonetheless sufficient to change
the localization of AP–HB-EGF–GFP to a homogenous distribution
over the cell surface (Fig. 5C). The same result was observed with
the mutation of all 12 basic amino acids in the HBD to alanine,
including those within the EGF-like domain (AP–113A-HB-EGF–
GFP) (Fig. 5D). Correct localization of HB-EGF to the plasma-
membrane fraction was observed in all HBD mutants, as well as
after treatment with heparin and heparinase III (see supplementary
material Fig. S4A). Additionally, paracrine stimulation with the
AP–113A-HB-EGF mutant activated the EGFR in the same manner
as AP–HB-EGF, suggesting that mutation of the HBD caused no
gross changes in molecular conformation (see supplementary
material Fig. S4B). The fraction of cell-surface HB-EGF at sites of
cell-cell contact was quantified with fluorescence microscopy by
measuring the area of acceptor-peptide-labeled HB-EGF that
overlapped with N-cadherin immunostaining divided by the total
HB-EGF area per cell. Treatment with heparin, heparinase III, or
mutation of the HBD (AP–113A-HB-EGF–GFP) led to a reduction
in the fraction of HB-EGF at sites of cell-cell contact from 0.8 to
between 0.25 and 0.35 (Fig. 5E). These data suggest that binding
of HB-EGF via the HBD to HSPGs on the cell surface is required
for HB-EGF localization to sites of cell-cell contact.
HSPGs interact with pro-HB-EGF in trans
Demonstrating that HSPGs were required for HB-EGF localization
to sites of cell-cell contact raised the question of the source of
HSPGs for this interaction. HB-EGF could interact in cis with
HSPGs on the same cell that expresses HB-EGF, holding it at sites
of cell-cell contact. Alternatively, HB-EGF might interact with
HSPGs in trans, and therefore HSPGs would be required on the
neighboring cell for localization to sites of cell-cell contact. To
distinguish between these two possibilities, CHO-K1 cells (wild
type) and CHOpgsD-677 cells (Lidholt et al., 1992), which are
heparan-sulfate deficient, were transfected with AP–HB-EGF–GFP
(green, Fig. 6) or mCherry (red, Fig. 6) and co-cultured together in
different combinations. The positive control (Fig. 6A) showed AP–
HB-EGF–GFP at sites of cell-cell contact between mCherry-
transfected and AP–HB-EGF–GFP-transfected wild-type CHO-K1
cells. Additionally, the negative control (Fig. 6D) showed no cell-
cell-contact localization of AP–HB-EGF–GFP between mCherry-
transfected and AP–HB-EGF–GFP-transfected CHOpgsD-677 cells.
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However, CHOpgsD-677 cells transfected with AP–HB-EGF–GFP
showed localization of HB-EGF to the sites of cell-cell contact with
a wild-type CHO-K1 mCherry-transfected neighbor (Fig. 6B). Wild-
type CHO-K1 cells transfected with AP–HB-EGF–GFP showed no
HB-EGF localization to sites of cell-cell contact with an mCherry-
transfected CHOpgsD-677 neighbor (Fig. 6C). Additionally, the
Fig. 5. The HBD targets pro-HB-EGF to sites of cell-cell contact. After 24
hours of plasmid transfection, the biotinylated, extracellular acceptor peptide
in the HB-EGF mutants was labeled with monovalent streptavidin–Alexa-
Fluor-568 (red, left) and imaged alongside the cytoplasmic tail of HB-EGF
conjugated to EGFP (green, middle) and phase contrast (right). (A)Deletion of
the portion of the HBD of AP–HB-EGF–GFP that lies outside of the EGF-like
domain (AP–delHBD-HB-EGF–GFP) led to a homogenous distribution of
HB-EGF over the cell surface. (B)Mutation of the first five positively charged
lysine residues in the HBD of HB-EGF to alanine (AP–97A-HB-EGF–GFP)
had no effect on the localization of the protein. (C)Mutation of all nine
positive lysine and arginine residues of the HBD, which lie outside the EGF-
like domain (AP–105A-HB-EGF–GFP), led to a more diffuse distribution of
HB-EGF over the cell surface; however, some remained localized at sites of
cell-cell contact. (D)Mutation of all 12 positive lysine and arginine residues in
the HBD of HB-EGF to alanine (AP–113A-HB-EGF–GFP), both those outside
and inside the EGF-like domain, led to a homogenous distribution of HB-EGF
over the cell surface. Each row represents the same field. Scale bars: 40m.
Arrowheads indicate sites of cell-cell contact. (E)The fraction of extracellular
streptavidin-labeled AP–HB-EGF–GFP that colocalized with N-cadherin
immunostaining was quantified from fluorescence micrographs. Mutation of
the HBD (AP–113A-HB-EGF–GFP) and treatment with heparin (100g/ml;
hep) or heparinase (10 mU/ml; hep’ase) significantly decreased the fraction of
HB-EGF that colocalized with N-cadherin at sites of cell-cell contact (n≥10,
*P<0.0005). NT, no treatment.
trans-bound AP–HB-EGF–GFP was dissociated from sites of cell-
cell contact with the addition of heparin (100 g/ml) for 15 minutes
or the HBD peptide (100 M) for 2 hours (Fig. 6E,F), resulting in a
diffuse localization. Because CHO cells do not express cadherins
(Niessen and Gumbiner, 2002), we were unable to study endogenous
cell-cell junctions. These data demonstrate that the localization of
pro-HB-EGF to sites of cell-cell contact is dependent on interaction
with HSPGs on a neighboring cell only, and thus pro-HB-EGF
interacts with HSPGs in trans.
Pro-HB-EGF interaction with HSPGs prevents ligand
cleavage
Because heparin dramatically changed the localization of pro-HB-
EGF from sites of cell-cell contact to a homogeneous distribution
over the cell surface, we hypothesized that this localization change
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might increase access to proteases and affect ligand cleavage. To
assess release of HB-EGF into the media, human placental alkaline
phosphatase was inserted into the extracellular domain of AP–HB-
EGF–GFP and AP–113A-HB-EGF–GFP near the N-terminus. The
addition of heparin (100 g/ml) increased alkaline-phosphatase
activity in the media (Fig. 7A) of confluent monolayers of COS-7
cells transfected with wild-type HB-EGF (AlkPhos–AP–HB-EGF–
GFP), suggesting that the heparin-induced localization change of
pro-HB-EGF away from sites of cell-cell contact upregulates ligand
cleavage. Treatment with the protease inhibitor batimastat (10 M)
inhibited heparin-induced cleavage of both wild-type and mutant
HB-EGF. Interestingly, the HBD-mutant alkaline-phosphatase
fusion (AlkPhos–AP–113A-HB-EGF–GFP) had higher levels of
cleavage compared with wild-type HB-EGF and was unaffected
further by the addition of heparin. Heparin increased the release of
HB-EGF into the media in a dose-dependent manner, with
concentrations above 1 g/ml leading to maximum release after 2
hours of treatment (Fig. 7B). These data suggest that the trans
interaction of pro-HB-EGF with HSPGs at sites of cell-cell contact
prevents proteolytic release of the ligand. The interaction of HB-
EGF with CD9, which also involves the HBD, might also serve to
inhibit proteolytic release of the ligand, because we found a similar
increase in alkaline-phosphatase activity in the medium for
AlkPhos–AP–113A-HB-EGF–GFP when using the HSPG-lacking
CHOpgsD-677 cells (see supplementary material Fig. S5). Because
the CD9 interaction seems to operate in cis (Sakuma et al., 1997),
and therefore ought not to depend on HB-EGF localization to sites
of cell-cell contact, the two HBD interactions might work in series
to provide a multi-layer control on ligand release. Despite the
upregulation in AP–113A-HBEGF release, no detectable difference
in EGFR phosphorylation at tyrosine 1148 was detected in cells
transfected with AP–113A-HB-EGF–GFP, AP–HB-EGF–GFP or
GFP (see supplementary material Fig. S4C). However, transfection
with AP–HB-EGF–GFP led to growth inhibition, because
[3H]thymidine incorporation was decreased 48% compared with a
GFP-transfected control (Fig. 7C). Interestingly, mutation of the
HBD of HB-EGF not only reversed the growth inhibition of HB-
EGF transfection, but also led to cell proliferation, with a 42%
increase in [3H]thymidine incorporation. Because HB-EGF
juxtacrine signaling has been reported to be growth inhibitory
(Iwamoto et al., 1999; Pan et al., 2002), we hypothesize that
mutation of the HBD decreases the juxtacrine interaction by
decreasing the concentration of pro-HB-EGF at sites of cell-cell
contact. Additionally, because mutation of the HBD increased the
rate of ligand cleavage from the cell surface, we hypothesize that
an increase in autocrine signaling stimulates cell proliferation.
These data would suggest that HSPGs might act as an important
regulator in the balance between juxtacrine and autocrine HB-
EGF, which can induce opposite cell fates of growth inhibition
versus proliferation.
Heparin binding controls amphiregulin localization, but
engineered heparin binding is insufficient for cell-cell-
contact localization
HB-EGF is not the only ligand in the EGFR family capable of
heparin binding, because amphiregulin, betacellulin and some
isoforms of neuregulin also interact with HSPGs. HB-EGF and
amphiregulin have similar HBDs located at the N-terminus of the
protein before the EGF-like domain. These domains are both 21
amino acids in length, with over half of the residues represented
by basic lysine or arginine, which allow the domain to interact
Fig. 6. HSPGs interact in trans with pro-HB-EGF. Confocal imaging of the
localization of HB-EGF (green) at the junction of an mCherry (red)-transfected
cell and an AP–HB-EGF–GFP-transfected cell. (A)Positive control sample with
AP–HB-EGF–GFP and mCherry both in CHO-K1 (wild-type) cells had HB-
EGF at sites of cell-cell contact (arrowheads). (B)Cis binding with AP–HB-
EGF–GFP in CHO-K1 (wild-type) cells and mCherry in CHO-pgsD677 cells
[– heparan sulfate (HS)] showed little HB-EGF at sites of cell-cell contact.
(C)Trans binding with AP–HB-EGF–GFP in CHOpgsD-677 (–HS) cells and
mCherry in CHO-K1 (wild-type) cells showed HB-EGF present at the cell-cell
junction (arrowheads). (D)Negative control sample with AP–HB-EGF–GFP and
mCherry in CHOpgsD-677 (–HS) cells showed no concentration of HB-EGF at
the cell-cell junction. Trans binding epifluorescence sample images were taken
before and after treatment with (E) heparin (100g/ml) for 15 minutes or (F) an
HBD peptide (100M) for 2 hours, which dissociated the ligand from sites of
cell-cell contact between an AP–HB-EGF–GFP transfected CHOpgsD-677
(–HS) cell and an mCherry-transfected CHO-K1 (wild-type) cell. Each
experiment was repeated three or more times. Scale bars: 20m.
with negatively charged heparin and heparan sulfate (Thompson et
al., 1994). We sought to test whether heparin changed the
localization of amphiregulin in the same manner as it does HB-
EGF to determine whether HSPG-mediated localization was a
common control mechanism for heparin-binding EGFR ligands.
Acceptor-peptide labeling of the extracellular portion of
amphiregulin, and a C-terminal GFP tag, showed that amphiregulin
is similar to HB-EGF in that the extracellular and intracellular
fluorophores were colocalized, suggesting that amphiregulin is
primarily present in the pro-form (Fig. 8A). Additionally,
amphiregulin was also concentrated around the perimeter of the
cell at sites of cell-cell contact and the addition of heparin (100
g/ml) for 4 hours led to a homogenous distribution of amphiregulin
over the cell surface (Fig. 8B). Similarly, mutation of all lysine and
arginine residues in the HBD of amphiregulin to alanine led to an
identical distribution (R.N.P., unpublished), suggesting that the
HBD of amphiregulin is also responsible for its localization to sites
of cell-cell contact.
To test whether the HBD of HB-EGF was sufficient to localize
any transmembrane protein to sites of cell-cell contact, we
engineered an artificial protein consisting of an extracellular
acceptor-peptide sequence followed by the portion of the HBD of
HB-EGF that lies outside the EGF-like domain (residues 93-105),
a 15-amino-acid flexible linker, cyan fluorescent protein (CFP),
then the transmembrane domain (TM) of the PDGF receptor. This
construct (AP-HBD-CFP-TM) (Fig. 8D) showed the same
homogenous localization over the cell surface as a control construct
(Fig. 8C) lacking an HBD (AP-CFP-TM). Therefore, the HBD
alone was insufficient to localize any protein to sites of cell-cell
contact. This suggests that an additional cofactor or specific
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structural feature of EGFR ligands is required for HB-EGF and
amphiregulin localization to sites of cell-cell contact.
Discussion
HSPGs, which are present on the cell surface and in the
extracellular matrix, are capable of binding many growth factors.
Traditionally, this interaction has been proposed to restrain soluble,
diffusible ligands, thus increasing their local concentration and
ability to activate receptors (Schlessinger et al., 1995).
Additionally, heparan-sulfate binding is known to modulate the
activity of signaling molecules and protect them from proteolytic
degradation (Conrad, 1998). Most ligands that have been reported
to interact with HSPGs are soluble secreted factors, such as
fibroblast growth factors (Gospodarowicz et al., 1984; Maciag et
al., 1984; Shing et al., 1984), vascular endothelial growth factor
(Ferrara and Henzel, 1989), hepatocyte growth factor (Nakamura
et al., 1984; Zhou et al., 1999) and platelet-derived growth factor
(Schilling et al., 1998). However, HSPGs also interact with some
growth factors that remain anchored to the cell surface via a
transmembrane domain, particularly those that belong to the
EGFR-ligand family, including HB-EGF (Higashiyama et al.,
1991), amphiregulin (Cook et al., 1991), betacellulin (Shing et al.,
1993) and certain isoforms of neuregulin (Holmes et al., 1992;
Loeb and Fischbach, 1995).
To extend our knowledge and understanding of the role of
HSPGs on growth-factor regulation, we investigated their
interactions with transmembrane pro-HB-EGF. One of our key
findings was that a trans interaction between HSPG and the HB-
EGF HBD is responsible for localizing pro-HB-EGF to sites of
cell-cell contact (Figs 2-6). HSPGs also modulated the localization
Fig. 7. Interaction with HSPGs reduces pro-HB-EGF cleavage and cell proliferation. (A)COS-7 cells transfected with wild-type HB-EGF (AlkPhos–AP–HB-
EGF–GFP) (circles) or the HBD mutant (AlkPhos–AP–113A-HB-EGF–GFP) (squares) were either pre-treated with 10M batimastat (+B) or PBS alone for 1
hour. Cells were stimulated with either 100g/ml of heparin (+H) alone (black dashed line) or heparin and batimastat (gray dashed line), or unstimulated (black
solid line) and media was collected at various time points, then cells were incubated with a 1.5 M salt solution for 60 seconds to release any soluble HB-EGF bound
to HSPGs. AlkPhos–AP–HB-EGF–GFP release is increased by treatment with heparin, and cleavage is further increased by mutating the HBD (AlkPhos–AP–
113A-HB-EGF–GFP). Pre-treatment with batimastat before the addition of heparin blocks both AlkPhos–AP–HB-EGF–GFP and AlkPhos–AP–113A-HB-EGF–
GFP cleavage. (B)Treatment for 2 hours with heparin (100g/ml) increases AlkPhos–AP–HB-EGF–GFP release in a dose-dependent manner. (A,B)Data shown
are average and standard deviation of three biological replicates from one of three independent experiments in which the same trend was observed.
(C)Incorporation of [3H]thymidine into cells transfected with GFP, AP–HB-EGF–GFP (HB-EGF) or AP–113A-HB-EGF–GFP (HBD mutant) for 24 hours shows
that HB-EGF transfection induces growth inhibition compared with GFP, whereas mutation of the HBD reverses the growth inhibition and promotes proliferation.
Results shown are normalized to GFP control and represent the average and standard deviation from four independent experiments with three or more biological
replicates per experiment (*P<0.05, **P<0.005).
of pro-amphiregulin in a similar manner (Fig. 8), suggesting that
this might be a common mechanism for transmembrane heparin-
binding ligands of the EGFR family. Because HB-EGF
(Higashiyama et al., 1995), amphiregulin (Inui et al., 1997) and
betacellulin (Tada et al., 1999) are heparin-binding and also capable
of signaling in a juxtacrine mode, the role of this interaction could
be to assist in sequestering prospective juxtacrine ligands at sites
of cell-cell contact to facilitate receptor binding, probably in concert
with CD9, to bind a receptor on a neighboring cell. This idea is
supported by the observation that the HBD of HB-EGF and
amphiregulin inhibits binding to the receptor except when in
complex with heparin or heparan sulfate (Higashiyama et al., 1993;
Johnson and Wong, 1994; Piepkorn et al., 1994; Takazaki et al.,
2004), and that presence of an intact HB-EGF N-terminus prevents
the ligand from activating its receptor during intracellular transport
(Dong et al., 2005). Together, these data support the idea that
HSPGs act as a permissive factor for juxtacrine signaling at sites
of cell-cell contact.
Using wild-type and mutant CHO cells lacking cell-surface
heparan sulfate, we demonstrated that the interaction of HSPGs
with pro-HB-EGF occurs in trans (Fig. 6). The localization of HB-
EGF to sites of cell-cell contact is unlikely to depend on interaction
with EGFR, because CHO-K1 cells lack endogenous EGFR yet
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still show strong localization of HB-EGF to sites of cell-cell
contact. This experiment also suggests that HSPGs are not required
as an intracellular chaperone for pro-HB-EGF during transport,
because cells lacking heparan sulfate were still able to localize
HB-EGF to the cell surface. HSPGs have previously been shown
to interact in trans with VEGFR-2 in VEGFR-mediated
angiogenesis (Jakobsson et al., 2006) and with the Xenopus receptor
caALK4 via the cofactor Vg1 during mesoderm migration in early
left-right development (Kramer and Yost, 2002). Additionally, this
interaction probably plays a role in blastocyst implantation during
pregnancy, because the interaction between HB-EGF on the lumenal
epithelium with EGFR and HSPGs on the adjacent blastocyst is
required for successful attachment, which is reduced by exogenous
heparin or blastocyst heparinase treatment (Farach et al., 1987;
Farach et al., 1988; Raab et al., 1996).
A further key finding from our work here is that exogenous
heparin and mutation of the HBD can upregulate HB-EGF
proteolytic release in COS-7 cells, suggesting that association with
HSPGs at sites of cell-cell contact protects pro-HB-EGF from
proteolysis (Fig. 7A). However, this protection is not likely to be
due to physical association of pro-HB-EGF with HSPGs, because
soluble heparin increased proteolytic cleavage of the ligand. We
speculate that the sequestration of pro-HB-EGF at sites of cell-cell
contact reduces access to metalloproteinases, consistent with
evidence that ectodomain cleavage is regulated at the substrate
level (Herrlich et al., 2008). Mutation of the HBD not only reversed
the growth inhibition observed with expression of pro-HB-EGF
(Fig. 7C), but also stimulated cell proliferation. We hypothesize
that the reversal of growth inhibition is due to a reduction in
juxtacrine signaling, because less HB-EGF is present at sites of
cell-cell contact when the HBD is not intact. Additionally, because
the HBD mutant is cleaved at a higher rate, this probably increases
autocrine HB-EGF signaling, stimulating cell growth. These data
suggest that interaction with HSPGs plays an important role in the
balance between juxtacrine and autocrine HB-EGF signaling and
the resulting opposite cell fates of growth inhibition versus
proliferation.
It is conceivable that heparin and heparan sulfate also operate in
vivo to dissociate pro-HB-EGF from HSPGs, thus stimulating
ligand cleavage. However, results reported here should be treated
with some caution, because experiments were performed in
transformed cells with overexpression of the ligand. In vivo, free
heparin is secreted by mast cells upon degranulation, and both
mast cells and HB-EGF signaling are implicated in the biological
processes of wound healing (for a review, see Noli and Miolo,
2001) (Tokumaru et al., 2000), as well as angiogenesis (for a
review, see Galinsky and Nechushtan, 2008) (Ongusaha et al.,
2004) and the pathogenesis of atherosclerosis (for a review, see
Kalesnikoff and Galli, 2008) (Nakata et al., 1996). Additionally,
dermal mast cells themselves express HB-EGF mRNA (Artuc et
al., 2002). Extracellular free heparan sulfate is generated by
degradation of cell-surface HSPGs with heparanase, the expression
of which is upregulated in all analyzed human cancers (Vlodavsky
et al., 2007). It is possible that heparanase leads to a local
concentration of free heparan sulfate that is high enough in the
interstitial space to dissociate pro-HB-EGF from sites of cell-cell
contact and stimulate cleavage of pro-HB-EGF. Fully understanding
these complicated effects will probably require detailed
mathematical modeling studies in the future along the lines
analogously undertaken for the fibroblast-growth-factor system
(Forsten-Williams et al., 2008).
Fig. 8. Pro-amphiregulin localization is changed by heparin, but the
addition of an HBD to other proteins was insufficient for localization to
sites of cell-cell contact. After 24 hours of plasmid transfection, the
biotinylated, extracellular acceptor peptide was labeled with monovalent
streptavidin–Alexa-Fluor-568 (red, left) and imaged alongside the cytoplasmic
tail of amphiregulin conjugated to EGFP (green, middle) or the CFP-tagged
control construct (cyan, middle), and phase contrast (right). (A)AP-AR-GFP
showed localization of the extracellular and intracellular domains to sites of
cell-cell contact (arrowheads). (B)Addition of heparin (100g/ml) for 4 hours
changed the localization of both the extracellular and intracellular domains of
AP-AR-GFP to a diffuse distribution over the cell surface, rather than at sites
of cell-cell contact. (C)The control construct AP-CFP-TM had a diffuse
localization of the protein over the cell surface, and (D) the addition of an
HBD to the control construct (AP-HBD-CFP-TM) did not alter this
localization. Each row represents the same field. Scale bars: 40m.
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Materials and Methods
Reagents
The following reagents were used: biotin (Sigma B4501), heparin (Sigma H3149),
heparan sulfate (Sigma H7640), chondroitin sulfate (Sigma C4384), heparinase III
(Sigma H8891), sodium chlorate (Sigma 244147), HBD peptide
KKKKKGKGLGKKRDPCLRKYK (Neopeptide),
Cell culture
COS-7 cells were cultured in high-glucose Dulbecco’s modified eagle medium
(DMEM) with L-glutamine (Gibco 11965), supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin. CHO-K1 and CHOpgsD-677 cells
(Lidholt et al., 1992) were cultured in Ham’s F12 media with L-glutamine
(BioWhittaker 12-615F), supplemented with 10% FBS and 1% penicillin-
streptomycin. For microscopy experiments, cells were plated on 35-mm glass-
bottom dishes (Mattek) coated with 0.1% gelatin (COS-7) or 1 g/ml of fibronectin
(CHO cells) for 1 hour at 37°C.
Plasmid constructs
The murine HB-EGF coding region was subcloned into pEGFP-N1 (Clontech)
using the EcoRI and XhoI restriction sites from an adenoviral plasmid (Yoshioka et
al., 2005). The acceptor peptide was inserted via site-directed mutagenesis (Geiser
et al., 2001) with the primer 5-GTGAAGTTGGGCGTGGCTAG CTCCCACC -
GAATTCTGCAGTCGACGGTACCGCGGGCC-3 and its reverse complement.
From here the following primers and their reverse complements were used to mutate
the HBD: AP-delHBD-HBEGF-GFP with 5-AAATCGAATGGCACGAA -
GGGGACCCATGCCTCAGGAAATA-3, AP-97A-HBEGF-GFP with 5-AAATC-
GAATGGCACGAAGGGGCGGCAGCCGCTGCGGGAAAGGGGTTAGGGAA-
GAAGA-3, AP-105A-HBEGF-GFP with 5-AAATCGAATGGCACGAA -
GGGGCGGCAGCCGCTGCGGGAGCAGGGTTAGGGGCGGCAGCCGACC-
CATGCCTCAGGAAATA-3 and AP-105A-HBEGF-GFP was used as the base
plasmids to make AP-113A-HBEGF-GFP with 5-CAGCCGACCCATGC-
CTCGCAGCGTACGCAGACTACTGCATCCACGGGGA-3. Human amphiregulin
cDNA was subcloned into pEGFP-N1 and the acceptor peptide inserted after V107
with the primer 5-TCAGTCAGAGTTGAACAG GTAGTTG GCCTGAACGAC -
ATCTTCGAAG CCC AGAAAATCGAATGGCACGAAAAGCCCCCCCAAAAC -
AAG-3 and its reverse complement. The HBD of HB-EGF (93-105) was inserted into
AP-CFP-TM (Chen et al., 2005) between CFP and the AP sequence to make AP-HBD-
CFP-TM with the primer 5-AGTGGCACGAG GGCGCGCCGAAAAAGAAGA -
AGAAAGG AAA GGGGTTAGGGAAGAAGAGAGCGGGCGGCATGGTGAG -
CAAGGGCGAGGA-3 and its reverse complement. Then, a flexible linker
(SEGGGSEGGTSGATG) was added between CFP and AP to allow the HBD better
access to HSPGs. This was done by PCR on AP-HBD-CFP-TM with the primer
5-GAAGAAGAGAGC GGGCGGCTCTGAAG GCGGC GGCAGCGAAGGCG G -
CACCAGCGGCG CGA CCGGAATGGTGAGCAAGGGCGAGGA-3 and its
reverse complement. Human placental alkaline phosphatase was amplified from a
human HB-EGF alkaline-phosphatase fusion protein (Raab et al., 1996) with forward
primer 5-CCTGGC CACCCCAAGC AAAG AAAGGAATATCATCCCAGTTGAG -
GAGGAGAA CCC GGACTTCTGGAACC GC-3 and reverse primer 5-TTT CT -
GGG CTTCG AAGATGTCG TTCAGGCCGTCGGTGGTGCCGGCGGGG-3. The
PCR product was gel purified and then used as the primer for a QuikChange insertion
modified for large inserts on the base plasmid AP–HB-EGF–GFP and AP–113A-HB-
EGF–GFP.
Purification of AP–HB-EGF
Three confluent 150-cm2 cell-culture dishes of COS-7 cells with 10 M biotin in the
media were transfected with AP–HB-EGF and BirA-ER or BirA-ER alone. After 24
hours, cell-culture media was replaced with serum-free media with 50 mM sodium
chlorate and 10 M biotin. After an additional 24 hours, the media was replaced with
phosphate buffered saline (PBS) with sodium and magnesium, 50 mM sodium
chlorate, 4 M phorbol 12-myristate 13-acetate (Sigma P8139), 0.0003% H2O2 and
10 M biotin. The following day, the PBS solution was collected after spinning out
dead cells and incubated at 4°C overnight with 50 l of heparin acrylic beads (Sigma
H5263). After washing with PBS, the biotinylated AP–HB-EGF was eluted from the
heparin beads with 50 l of 2 M NaCl in PBS. The concentration of biotinylated
AP–HB-EGF was estimated by western blotting with streptavidin-HRP in comparison
with a standard of biotinylated acceptor-peptide-tagged maltose-binding protein
(Avidity BIS-300).
Bioactivity of AP–HB-EGF
COS-7 cells were serum starved for 24 hours and stimulated for 1 minute with
recombinant human HB-EGF (R&D Systems, 259-HE), heparin-bead-purified
biotinylated AP–HBEGF or an equal volume of a control heparin-bead eluant. Cells
were washed with PBS, then lysed with RIPA buffer [PBS with 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 0.57 mM PMSF,
protease inhibitor cocktail (Sigma P8340), and phosphatase inhibitor cocktail II
(Sigma P5725)]. Lysates were subjected to SDS-PAGE and immunoblotted for total
EGFR (C74B9) (Cell Signaling Technology, 2464) and phospho-EGFR Tyr1148
(Cell Signaling Technology, 4404) according to standard protocols. This experiment
was repeated twice.
Biotinylation and cell-surface labeling of the acceptor peptide
Acceptor-peptide fusion constructs and a variant of BirA that was engineered to
localize to the ER (BirA-ER) (Howarth and Ting, 2008) were co-transfected into
COS-7 cells with Fugene6 or Mirus LTI Transfection reagent at equal molar ratios
and cell-culture media was supplemented with 10 M biotin. After 24 hours, cells
were washed with PBS with calcium and magnesium and the acceptor peptide was
labeled with mSA-AF568 or streptavidin-Cy5 (Invitrogen 43-8316) at 1 g/ml in 5%
dialyzed bovine serum albumin (BSA) in PBS for 10 minutes on ice. Cells were
washed twice with PBS before imaging and imaged in PBS. Monovalent streptavidin–
Alexa-Fluor-568 was produced as previously published (Howarth et al., 2006;
Howarth and Ting, 2008). Each fluorescent labeling experiment was repeated three
or more times, with 20 or more cells evaluated per experiment.
Immunostaining and fluorescence quantification
Cells were fixed with 2% paraformaldehyde for 10 minutes, blocked with 5% horse
serum, incubated with anti-N-cadherin (H-63) antibody (Santa Cruz 7939) at 1:50,
then anti-rabbit AF568 (Invitrogen A11011) at 1:500. The area in pixels for N-
cadherin immunostaining and streptavidin-fluorophore-labeled extracellular HB-
EGF was measured from fluorescence micrographs using thresholding with the
ImageJ software package to define positive fluorescence. An N-cadherin mask was
then applied to the HB-EGF images to quantify the number of pixels per cell that
overlapped N-cadherin compared with the total number of HB-EGF-positive pixels.
Alkaline-phosphatase cleavage assay
COS-7 cells were plated on 96-well dishes (6500 cells per well) for 1 day, then
transfected with AlkPhos–AP–HB-EGF–GFP or AlkPhos–AP–113A-HB-EGF–GFP.
The following day, designated samples were pre-treated with batimastat (10 M) in
PBS with calcium and magnesium for 1 hour, then stimulated with a 100 l solution
of heparin in PBS supplemented with 1% BSA. Supernatants were collected at
various time points, then washed for 1 minute with 100 l of 1.5 M NaCl in PBS
supplemented with 1% BSA to remove any soluble HB-EGF bound to HSPGs. The
salt wash was combined with the supernatant and 40 l was combined with 100 l
of p-nitrophenyl phosphate (Millipore ES009), incubated for 2 hours at 37°C, then
optical density was read at 410 nm.
[3H]thymidine incorporation
COS-7 were plated at 25,000 cells per well in a 12-well dish (BD Falcon) for 24
hours, then transfected and serum starved. After 1 day, 1 Ci/ml of [3H]thymidine
(Perkin Elmer NET027E001MC) was added for 3 hours, then the cells were washed
with PBS and 5% tricholoroacetic acid, and lysed with 1 ml of 0.1 N NaOH + 0.1%
SDS. After the addition of 4 ml of scintillation cocktail (Ecolume 88247005),
samples were read on a Beckman Coulter LS6500 scintillation counter.
Microscopy
Phase-contrast and fluorescent images were obtained with a digital CCD camera
(CoolSNAP HQ, Roper Scientific) and an inverted microscope (Olympus IX-70)
with a 20 phase-contrast objective (Olympus LCPlanF NA 0.40) or 40 water-
immersion objective (Olympus UApo/340 NA 1.15) for fluorescence. Confocal
images were acquired at 60 with a Nikon TE2000-U inverted microscope.
Statistical analysis
A two-tailed, unpaired Student’s t-test assuming unequal variance was utilized.
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